Article
Biochemistry & Molecular Biology
Natalia Izycka, Mikolaj Piotr Zaborowski, Lukasz Ciecierski, Kamila Jaz, Sebastian Szubert, Cezary Miedziarek, Marta Rezler, Kinga Piatek-Bajan, Aneta Synakiewicz, Anna Jankowska, Marek Figlerowicz, Karolina Sterzynska, Ewa Nowak-Markwitz
Summary: This study aimed to identify cancer stem cell markers and their association with clinical outcomes in High-Grade Serous Ovarian Cancer. The results showed that ALDH1A1, CD44, EPCAM, LGR5, POU5F1, and THY1 levels may serve as prognostic factors and help predict treatment response in ovarian cancer.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Yingqing Deng, Yuan Tan, Dongmei Zhou, Youhuang Bai, Ting Cao, Caizhou Zhong, Weilai Huang, Yuhua Ou, Linlang Guo, Qianqian Liu, Deling Yin, Lipai Chen, Xiping Luo, Deqiang Sun, Xiujie Sheng
Summary: This study investigated the molecular mechanism and biology of metastatic high-grade serous ovarian cancer (HG_M) through single-cell RNA sequencing analysis. The findings revealed amplified genes in metastatic tumors, malignant cells exhibiting features of epithelial-mesenchymal transition (EMT) associated with poor prognosis, and enrichment of cancer-associated fibroblasts with EMT-program involved in angiogenesis and immune regulation. Compared to another subtype, high-grade serous ovarian cancer showed higher T cell infiltration.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Yuri Belotti, Elaine Hsuen Lim, Chwee Teck Lim
Summary: In this study, a 19-gene TME-related HGSOC prognostic genetic panel was identified using bioinformatics methods, and an association between tumor-infiltrating immune cells and mortality rates was found.
Article
Biology
Emilee N. Kotnik, Mary M. Mullen, Nicholas C. Spies, Tiandao Li, Matthew Inkman, Jin Zhang, Fernanda Martins-Rodrigues, Ian S. Hagemann, Carolyn K. McCourt, Premal H. Thaker, Andrea R. Hagemann, Matthew A. Powell, David G. Mutch, Dineo Khabele, Gregory D. Longmore, Elaine R. Mardis, Christopher A. Maher, Christopher A. Miller, Katherine C. Fuh
Summary: Analysis of genomic and transcriptomic alterations in primary and metastatic tumors of high-grade serous ovarian cancer patients reveals differences associated with survival outcomes, providing insights for personalized treatment options and drug development.
COMMUNICATIONS BIOLOGY
(2023)
Article
Multidisciplinary Sciences
I-M Launonen, N. Lyytikainen, J. Casado, E. A. Anttila, A. Szabo, U-M Haltia, C. A. Jacobson, J. R. Lin, Z. Maliga, B. E. Howitt, K. C. Strickland, S. Santagata, K. Elias, A. D. D'Andrea, P. A. Konstantinopoulos, P. K. Sorger, A. Farkkila
Summary: In this study, the authors used highly multiplexed imaging to analyze the immune microenvironment of high-grade serous ovarian cancers (HGSOC) and identified phenotypic characteristics and spatial interactions associated with BRCA1/2 gene mutations. These findings have important implications for improving immunotherapeutic strategies and patient stratification.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Chiara M. Biatta, Michele Paudice, Marco Greppi, Veronica Parrella, Alessia Parodi, Giuseppa De Luca, Gianna Maria Cerruti, Serafina Mammoliti, Cinzia Caroti, Paola Menichini, Gilberto Fronza, Silvia Pesce, Emanuela Marcenaro, Valerio G. Vellone
Summary: This study investigated the concordance between immunohistochemical p53 staining and TP53 mutations in HGSOC, and explored prognostic differences between p53 overexpression and null expression groups. The results showed that all cases with a null immunohistochemical p53 expression had TP53 mutations, while 16 out of 18 cases with p53 overexpression had TP53 missense mutations. Follow-up data revealed a significant reduction in overall survival for the p53 null group. Therefore, immunohistochemical assay can serve as a reliable surrogate for TP53 mutations, and HGSOC with p53 null mutations are associated with a more aggressive subtype.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Cherie-Ann Nathan, Alok R. Khandelwal, Gregory T. Wolf, Juan P. Rodrigo, Antti A. Makitie, Nabil F. Saba, Arlene A. Forastiere, Carol R. Bradford, Alfio Ferlito
Summary: This review summarizes the current evidence and impact of TP53 mutations in head and neck squamous cell carcinomas (HNSCC), including their association with tumor invasion, metastasis, genomic instability, and cell proliferation, as well as their link to increased aggressiveness and reduced survival after surgical treatment of HNSCC.
MOLECULAR CARCINOGENESIS
(2022)
Article
Genetics & Heredity
Dale W. Garsed, Ahwan Pandey, Sian Fereday, Catherine J. Kennedy, Kazuaki Takahashi, Kathryn Alsop, Phineas T. Hamilton, Joy Hendley, Yoke-Eng Chiew, Nadia Traficante, Pamela Provan, Dinuka Ariyaratne, George Au-Yeung, Nicholas W. Bateman, Leanne Bowes, Alison Brand, Elizabeth L. Christie, Julie M. Cunningham, Michael Friedlander, Bronwyn Grout, Paul Harnett, Jillian Hung, Bryan McCauley, Orla McNally, Anna M. Piskorz, Flurina A. M. Saner, Robert A. Vierkant, Chen Wang, Stacey J. Winham, Paul D. P. Pharoah, James D. Brenton, Thomas P. Conrads, George L. Maxwell, Susan J. Ramus, Celeste Leigh Pearce, Malcolm C. Pike, Brad H. Nelson, Ellen L. Goode, Anna DeFazio, David D. L. Bowtell
Summary: This study analyzed the genomic, transcriptomic, and methylomic profiles of patients with advanced-stage HGSC who survived more than 10 years after diagnosis. Long-term survivors had more alterations in DNA repair genes and higher neoantigen load. Patients were clustered into survival groups based on genomic and immune cell signatures, including different subsets of patients with BRCA1 alterations. Specific combinations of genetic and immune factors contribute to long-term survival in HGSC.
Review
Oncology
Lana E. Kandalaft, Denarda Dangaj Laniti, George Coukos
Summary: This review proposes a classification system based on immunophenotypes to explain the failures of existing immunotherapies in high-grade serous ovarian cancers, and suggests that rational therapeutic approaches tailored to each immunophenotype might meet with improved success.
NATURE REVIEWS CANCER
(2022)
Review
Biochemistry & Molecular Biology
Paula Punzon-Jimenez, Victor Lago, Santiago Domingo, Carlos Simon, Aymara Mas
Summary: High-grade serous ovarian carcinoma (HGSOC) is the most common form of epithelial ovarian carcinoma, and its early diagnosis still relies on traditional methods. Research on its etiopathogenesis provides new insights for finding early detection methods.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Oncology
Li Zhao, Sara Corvigno, Shaolin Ma, Joseph Celestino, Nicole D. Fleming, Richard A. Hajek, Adrian Lankenau Ahumada, Nicholas B. Jennings, Erika J. Thompson, Hongli Tang, Shannon N. Westin, Amir A. Jazaeri, Jianhua Zhang, P. Andrew Futreal, Anil K. Sood, Sanghoon Lee
Summary: This study aimed to investigate if a simple blood sample can predict the response of ovarian cancer patients to treatment. The results showed that circulating extracellular vesicles isolated at diagnosis can distinguish between patients who will respond differently to the treatment, potentially serving as a novel predictive marker.
Article
Oncology
Chiho Miyagawa, Hidekatsu Nakai, Tomoyuki Otani, Ryusuke Murakami, Shiki Takamura, Hisamitsu Takaya, Kosuke Murakami, Masaki Mandai, Noriomi Matsumura
Summary: We modified the histopathologic subtyping algorithm to achieve high interobserver agreement in whole slide imaging and characterized the tumor biology of MT type for treatment individualization. The results showed that MT type had a worse prognosis and genes related to angiogenesis and immune response were highly expressed in the MT type. The findings of this study may be useful for treatment individualization of HGSOC, including angiogenesis inhibitors and immunotherapy.
JOURNAL OF GYNECOLOGIC ONCOLOGY
(2023)
Article
Oncology
Qian Hao, Jiajia Li, Qinghua Zhang, Fei Xu, Bangxiang Xie, Hua Lu, Xiaohua Wu, Xiang Zhou
Summary: This study using single-cell transcriptomics analysis of HGSOC samples reveals new molecular features and potential therapeutic targets, which could advance the understanding and treatment of the disease.
CLINICAL AND TRANSLATIONAL MEDICINE
(2021)
Article
Medicine, Research & Experimental
Yuanzhi Chen, Zhicheng He, Shuting Yang, Cheng Chen, Wenyong Xiong, Yingying He, Shubai Liu
Summary: In this study, it was found that RUNX1 plays a crucial role in the development of high-grade serous ovarian cancer (HGSOC). It regulates apoptosis and EMT function, impacting the physiological function of ovarian cancer cells. Down-regulation of RUNX1 increases sensitivity to drug therapy for ovarian cancer. This research has significant implications for the diagnosis and treatment of HGSOC patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2023)
Article
Oncology
Luuk Harbers, Federico Agostini, Marcin Nicos, Dimitri Poddighe, Magda Bienko, Nicola Crosetto
Summary: SCNAs are a common feature of human cancers, affecting the dosage of multiple genes and promoting tumorigenesis. A comprehensive analysis of 853,218 SCNAs from 10,729 tumor samples across 32 cancer types using TCGA data was conducted, discussing current models for their generation during carcinogenesis and their clinical implications, while also highlighting unresolved questions in the field.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Delores J. Grant, Ani Manichaikul, Anthony J. Alberg, Elisa Bandera, Jill Barnholtz-Sloan, Melissa Bondy, Michele L. Cote, Ellen Funkhouser, Patricia G. Moorman, Lauren C. Peres, Edward S. Peters, Ann G. Schwartz, Paul D. Terry, Xin-Qun Wang, Temitope O. Keku, Cathrine Hoyo, Andrew Berchuck, Dale P. Sandler, Jack A. Taylor, Katie M. O'Brien, Digna R. Velez Edwards, Todd L. Edwards, Alicia Beeghly-Fadiel, Nicolas Wentzensen, Celeste Leigh Pearce, Anna H. Wu, Alice S. Whittemore, Valerie McGuire, Weiva Sieh, Joseph H. Rothstein, Francesmary Modugno, Roberta Ness, Kirsten Moysich, Mary Anne Rossing, Jennifer A. Doherty, Thomas A. Sellers, Jennifer B. Permuth-Way, Alvaro N. Monteiro, Douglas A. Levine, Veronica Wendy Setiawan, Christopher A. Haiman, Loic LeMarchand, Lynne R. Wilkens, Beth Y. Karlan, Usha Menon, Susan Ramus, Simon Gayther, Aleksandra Gentry-Maharaj, Kathryn L. Terry, Daniel W. Cramer, Ellen L. Goode, Melissa C. Larson, Scott H. Kaufmann, Rikki Cannioto, Kunle Odunsi, John L. Etter, Ruea-Yea Huang, Marcus Q. Bernardini, Alicia A. Tone, Taymaa May, Marc T. Goodman, Pamela J. Thompson, Michael E. Carney, Shelley S. Tworoger, Elizabeth M. Poole, Diether Lambrechts, Ignace Vergote, Adriaan Vanderstichele, Els Van Nieuwenhuysen, Hoda Anton-Culver, Argyrios Ziogas, James D. Brenton, Line Bjorge, Helga B. Salvensen, Lambertus A. Kiemeney, Leon F. A. G. Massuger, Tanja Pejovic, Amanda Bruegl, Melissa Moffitt, Linda Cook, Nhu D. Le, Angela Brooks-Wilson, Linda E. Kelemen, Paul D. P. Pharoah, Honglin Song, Ian Campbell, Diana Eccles, Anna DeFazio, Catherine J. Kennedy, Joellen M. Schildkraut
Article
Biochemistry & Molecular Biology
Yongchao Dou, Emily A. Kawaler, Daniel Cui Zhou, Marina A. Gritsenko, Chen Huang, Lili Blumenberg, Alla Karpova, Vladislav A. Petyuk, Sara R. Savage, Shankha Satpathy, Wenke Liu, Yige Wu, Chia-Feng Tsai, Bo Wen, Zhi Li, Song Cao, Jamie Moon, Zhiao Shi, MacIntosh Cornwell, Matthew A. Wyczalkowski, Rosalie K. Chu, Suhas Vasaikar, Hua Zhou, Qingsong Gao, Ronald J. Moore, Kai Li, Sunantha Sethuraman, Matthew E. Monroe, Rui Zhao, David Heiman, Karsten Krug, Karl Clauser, Ramani Kothadia, Yosef Maruvka, Alexander R. Pico, Amanda E. Oliphant, Emily L. Hoskins, Samuel L. Pugh, Sean J. I. Beecroft, David W. Adams, Jonathan C. Jarman, Andy Kong, Hui-Yin Chang, Boris Reva, Yuxing Liao, Dmitry Rykunov, Antonio Colaprico, Xi Steven Chen, Andrzej Czekanski, Marcin Jedryka, Rafa Matkowski, Maciej Wiznerowicz, Tara Hiltke, Emily Boja, Christopher R. Kinsinger, Mehdi Mesri, Ana I. Robles, Henry Rodriguez, David Mutch, Katherine Fuh, Matthew J. Ellis, Deborah DeLair, Mathangi Thiagarajan, D. R. Mani, Gad Getz, Michael Noble, Alexey I. Nesvizhskii, Pei Wang, Matthew L. Anderson, Douglas A. Levine, Richard D. Smith, Samuel H. Payne, Kelly V. Ruggles, Karin D. Rodland, Li Ding, Bing Zhang, Tao Liu, David Fenyo
Article
Oncology
Melissa K. Frey, Sarah S. Lee, Deanna Gerber, Zachary P. Schwartz, Jessica Martineau, Kathleen Lutz, Erin Reese, Emily Dalton, Annie Olsen, Julia Girdler, Bhavana Pothuri, Leslie Boyd, John P. Curtin, Douglas A. Levine, Stephanie Blank
GYNECOLOGIC ONCOLOGY
(2020)
Article
Oncology
Panagiotis A. Konstantinopoulos, Barbara Norquist, Christina Lacchetti, Deborah Armstrong, Rachel N. Grisham, Paul J. Goodfellow, Elise C. Kohn, Douglas A. Levine, Joyce F. Liu, Karen H. Lu, Dorinda Sparacio, Christina M. Annunziata
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Oncology
J. Millstein, T. Budden, E. L. Goode, M. S. Anglesio, A. Talhouk, M. P. Intermaggio, H. S. Leong, S. Chen, W. Elatre, B. Gilks, T. Nazeran, M. Volchek, R. C. Bentley, C. Wang, D. S. Chiu, S. Kommoss, S. C. Y. Leung, J. Senz, A. Lum, V Chow, H. Sudderuddin, R. Mackenzie, J. George, S. Fereday, J. Hendley, N. Traficante, H. Steed, J. M. Koziak, M. Kobel, I. A. McNeish, T. Goranova, D. Ennis, G. Macintyre, D. Silva De Silva, T. Ramon y Cajal, J. Garcia-Donas, S. Hernando Polo, G. C. Rodriguez, K. L. Cushing-Haugen, H. R. Harris, C. S. Greene, R. A. Zelaya, S. Behrens, R. T. Fortner, P. Sinn, E. Herpel, J. Lester, J. Lubinski, O. Oszurek, A. Toloczko, C. Cybulski, J. Menkiszak, C. L. Pearce, M. C. Pike, C. Tseng, J. Alsop, V Rhenius, H. Song, M. Jimenez-Linan, A. M. Piskorz, A. Gentry-Maharaj, C. Karpinskyj, M. Widschwendter, N. Singh, C. J. Kennedy, R. Sharma, P. R. Harnett, B. Gao, S. E. Johnatty, R. Sayer, J. Boros, S. J. Winham, G. L. Keeney, S. H. Kaufmann, M. C. Larson, H. Luk, B. Y. Hernandez, P. J. Thompson, L. R. Wilkens, M. E. Carney, B. Trabert, J. Lissowska, L. Brinton, M. E. Sherman, C. Bodelon, S. Hinsley, L. A. Lewsley, R. Glasspool, S. N. Banerjee, E. A. Stronach, P. Haluska, I Ray-Coquard, S. Mahner, B. Winterhoff, D. Slamon, D. A. Levine, L. E. Kelemen, J. Benitez, J. Chang-Claude, J. Gronwald, A. H. Wu, U. Menon, M. T. Goodman, J. M. Schildkraut, N. Wentzensen, R. Brown, A. Berchuck, G. Chenevix-Trench, A. DeFazio, S. A. Gayther, M. J. Garcia, M. J. Henderson, M. A. Rossing, A. Beeghly-Fadiel, P. A. Fasching, S. Orsulic, B. Y. Karlan, G. E. Konecny, D. G. Huntsman, D. D. Bowtell, J. D. Brenton, J. A. Doherty, P. D. P. Pharoah, S. J. Ramus
ANNALS OF ONCOLOGY
(2020)
Review
Oncology
Marc Tischkowitz, Sidong Huang, Susana Banerjee, Jennifer Hague, William P. D. Hendricks, David G. Huntsman, Jessica D. Lang, Krystal A. Orlando, Amit M. Oza, Patricia Pautier, Isabelle Ray-Coquard, Jeffrey M. Trent, Michael Witcher, Leora Witkowski, W. Glenn McCluggage, Douglas A. Levine, William D. Foulkes, Bernard E. Weissman
CLINICAL CANCER RESEARCH
(2020)
Editorial Material
Multidisciplinary Sciences
Victoria L. Bae-Jump, Douglas A. Levine
Article
Genetics & Heredity
Honglin Song, Ed M. Dicks, Jonathan Tyrer, Maria Intermaggio, Georgia Chenevix-Trench, David D. Bowtell, Nadia Traficante, James Brenton, Teodora Goranova, Karen Hosking, Anna Piskorz, Elke van Oudenhove, Jen Doherty, Holly R. Harris, Mary Anne Rossing, Matthias Duerst, Thilo Dork, Natalia Bogdanova, Francesmary Modugno, Kirsten Moysich, Kunle Odunsi, Roberta Ness, Beth Y. Karlan, Jenny Lester, Allan Jensen, Susanne Kruger Kjaer, Estrid Hogdall, Ian G. Campbell, Conxi Lazaro, Miguel Angel Pujara, Julie Cunningham, Robert Vierkant, Stacey J. Winham, Michelle Hildebrandt, Chad Huff, Donghui Li, Xifeng Wu, Yao Yu, Jennifer B. Permuth, Douglas A. Levine, Joellen M. Schildkraut, Marjorie J. Riggan, Andrew Berchuck, Penelope M. Webb, Cezary Cybulski, Jacek Gronwald, Anna Jakubowska, Jan Lubinski, Jennifer Alsop, Patricia Harrington, Isaac Chan, Usha Menon, Celeste L. Pearce, Anna H. Wu, Anna de Fazio, Catherine J. Kennedy, Ellen Goode, Susan Ramus, Simon Gayther, Paul Pharoah
Summary: This study aimed to investigate the contribution of rare deleterious germline variants in candidate genes to ovarian cancer susceptibility. The findings suggest a potential association between PALB2 mutations and increased risk of high-grade serous ovarian cancer, with further research needed to confirm the significance of other genes.
JOURNAL OF MEDICAL GENETICS
(2021)
Article
Oncology
Alexander Shushkevich, Premal H. Thaker, Ramey D. Littell, Naishadh A. Shah, Sarah Chiang, Katherine Thornton, Martee L. Hensley, Brian M. Slomovitz, Kevin M. Holcomb, Mario M. Leitao, Michael D. Toboni, Matthew A. Powell, Douglas A. Levine, Sean C. Dowdy, Ann Klopp, Jubilee Brown
GYNECOLOGIC ONCOLOGY
(2020)
Review
Oncology
Amnon A. Berger, Fanny Dao, Douglas A. Levine
Summary: Endometrial carcinoma is the most common gynecologic malignancy in the modern world, with limited therapeutic options. Researchers have been trying to identify prognostic and therapeutic biomarkers, with recent trials shedding new light on possible treatment strategies.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Harini Veeraraghavan, Herbert Alberto Vargas, Sanchez Alejandro-Jimenez, Maura Micco, Eralda Mema, Yulia Lakhman, Mireia Crispin-Ortuzar, Erich P. Huang, Douglas A. Levine, Rachel N. Grisham, Nadeem Abu-Rustum, Joseph O. Deasy, Alexandra Snyder, Martin L. Miller, James D. Brenton, Evis Sala
Article
Oncology
Kimberly K. Leslie, Virginia L. Filiaci, Adrianne R. Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley, Debra Richardson, David Mutch, Angeles Alvarez Secord, Krishnansu S. Tewari, Megan E. McDonald, Cara Mathews, Casey Cosgrove, Summer Dewdney, Yovanni Casablanca, Amanda Jackson, Peter G. Rose, XunClare Zhou, Michael McHale, Heather Lankes, Douglas A. Levine, Carol Aghajanian
Summary: The study suggests that mutations in the TP53 gene are associated with improved progression-free survival (PFS) and overall survival (OS) in advanced endometrial cancer patients receiving bevacizumab, compared to temsirolimus. This indicates that TP53 mutational status may serve as a potential biomarker for guiding treatment choices in endometrial cancer patients.
GYNECOLOGIC ONCOLOGY
(2021)
Article
Oncology
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessandro D. Santin, Paul Goodfellow, Douglas A. Levine, Martin Kobel, Stefan Kommoss, Tjalling Bosse, C. Blake Gilks, Aline Talhouk
Summary: Endometrial cancers with pathogenic POLE mutations are not associated with traditional risk parameters, and patients do not seem to benefit from adjuvant therapy. Low rates of recurrence/progression and high salvage rates may allow for safely decreasing treatment intensity for these patients.
Article
Oncology
Jessica N. McAlpine, Derek S. Chiu, Remi A. Nout, David N. Church, Pascal Schmidt, Stephanie Lam, Samuel Leung, Stefania Bellone, Adele Wong, Sara Y. Brucker, Cheng Han Lee, Blaise A. Clarke, David G. Huntsman, Marcus Q. Bernardini, Joanne Ngeow, Alessandro D. Santin, Paul Goodfellow, Douglas A. Levine, Martin Kobel, Stefan Kommoss, Tjalling Bosse, C. Blake Gilks, Aline Talhouk
Summary: Patients with ECs harboring pathogenic POLE mutations do not benefit from adjuvant therapy, as these mutations are not associated with most traditional risk parameters, and they exhibit low rates of adverse events with high and sustained salvage rates in cases of recurrence.
Article
Oncology
Shuang Zhang, Sonia Iyer, Hao Ran, Igor Dolgalev, Shengqing Gu, Wei Wei, Connor J. R. Foster, Cynthia A. Loomis, Narciso Olvera, Fanny Dao, Douglas A. Levine, Robert A. Weinberg, Benjamin G. Neel
Summary: Genetically informed, immunocompetent tumor models are crucial for evaluating conventional, targeted, and immune therapies. By engineering mouse fallopian tube organoids, researchers were able to study the effects of specific mutations found in high-grade serous tubo-ovarian cancer (HGSC) models, leading to the development of effective combination treatments for different genetic subgroups of HGSC. These findings highlight the importance of genotype-informed, syngeneic organoid models for understanding tumor biology and therapeutic responses.